Patients Coming Off Weight-Loss Injections Regain Pounds at a Quadrupled Rate Than People Using Diet and Exercise

New research indicates that people who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who end conventional diet and exercise regimens.

Research printed in a leading health publication shows that while overweight people can lose substantial amounts of their body weight while using the jabs, the weight is regained at an average rate of 0.8 kg per month upon discontinuation.

"Individuals purchasing these treatments should be aware of the risk of rapid weight regain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.

This pace of recovery implies a return to starting weight in about one and a half years.

Comparing Treatments

The analysis, which examined dozens of trials involving thousands of patients, compared the effects of GLP-1 agonists with older methods.

Researchers emphasize that individuals who shed pounds through lifestyle changes alone usually see a more gradual creep back—around 100 grams monthly—post-intervention.

The Reason for the Quick Rebound

Doctors suggest the way of the injections accounts for the amplified regain.

GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.

"Sustained high doses of the hormone levels far above than normal may cause the system to generate a reduced amount of its endogenous hormone, and may also reduce sensitivity to its actions," explained Dr. Adam Collins, a dietetics expert.

"Discontinuation of this medication leads to appetite is uncontrolled, making overeating much more probable."

A Lifelong Issue?

The NHS advise the injections for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.

Many experts contend that, due to the significant potential of relapse, the treatment should be considered life-long.

This view is echoed by drug manufacturers, who state that the results "underscore the persistent character of obesity," similar to managing conditions like diabetes.

User Experiences

Users who have discontinued the medication explain a intense resurgence of hunger.

"It felt as if a trigger that goes on and you become ravenous," described a patient.

This difficulty is worsened if users have not developed lasting lifestyle or habit changes during therapy.

Significant Adoption

Survey data indicate that millions of people in the UK have used these injections in the past year, with desire remaining high.

• Adoption is higher among females than men.
• The 40s and 50s age group shows the greatest usage rates.
• Many access the medications through private healthcare rather than the NHS.

Ultimately, clinicians emphasize that while the jabs are powerful agents for shedding pounds, they are not a standalone fix and maintained weight loss hinges on ongoing behavioural support.